Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate

被引：0
|
作者：
R. A. Wermers
C. P. Recknor
F. Cosman
L. Xie
E. V. Glass
J. H. Krege
机构：
[1] Mayo Clinic,Division of Endocrinology and Metabolism
[2] United Osteoporosis Centers,Clinical Research Center
[3] Helen Hayes Hospital,Eli Lilly and Company
[4] Lilly Corporate Center,undefined
来源：
Osteoporosis International | 2008年 / 19卷
关键词：
Alendronate; Hypercalcemia; Postmenopausal osteoporosis; Raloxifene; Serum calcium; Teriparatide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1055 / 1065
页数：10
相关论文
共 50 条
  • [41] Effects of alendronate treatment on serum levels of osteoprotegerin and total RANKL in women with postmenopausal osteoporosis
    Reyes-García, R
    Fernández-García, D
    Mezquita-Raya, P
    De la Higuera, M
    Alonso, G
    Ruiz-Requena, ME
    Escobar-Jiménez, F
    Muñoz-Torres, M
    BONE, 2005, 36 : S410 - S411
  • [42] Effects of two years treatment with teriparatide on bone mineral density in women with postmenopausal osteoporosis previously treated with anti-resorptive agents
    Michaud, M.
    CAHIERS DE L ANNEE GERONTOLOGIQUE, 2010, 2 (03): : 159 - 162
  • [43] Raloxifene increases intestinal calcium absorption in elderly postmenopausal women with osteoporosis
    Vokrouhlicka, J
    Sysalova, J
    Stepan, JJ
    BONE, 2005, 36 : S439 - S439
  • [44] Effect of raloxifene after recombinant teriparatide [hPTH(1–34)] treatment in postmenopausal women with osteoporosis
    S. Adami
    J. San Martin
    M. Muñoz-Torres
    M. J. Econs
    L. Xie
    G. P. Dalsky
    M. McClung
    D. Felsenberg
    J. P. Brown
    M. L. Brandi
    A. Sipos
    Osteoporosis International, 2008, 19 : 87 - 94
  • [45] Postmenopausal women with osteoporosis: experience when treated with teriparatide in clinical practice
    Ish-Shalom, Sophia
    Dumitrache, Constantin
    El-Husseini, Timour Fikry
    Hussein, Azza
    Barker, Clare
    Pavo, Imre
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (02) : 343 - 353
  • [46] THE EFFECT OF TERIPARATIDE ON BONE MATERIAL PROPERTIES IS NOT DIFFERENT IN POSTMENOPAUSAL WOMEN WHO WERE PREVIOUSLY TREATMENT-NAIVE OR TREATED WITH ALENDRONATE
    Buchinger, Birgit
    Gamsjaeger, Sonja
    Dobnig, Harald
    Stepan, Jan
    Burr, David
    Petto, Helmut
    Pavo, Imre
    Klaushofer, Klaus
    Paschalis, Eleftherios
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : 286 - 286
  • [47] The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis
    Genant, HK
    Halse, J
    Briney, WG
    Xie, L
    Glass, EV
    Krege, JH
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (07) : 1027 - 1034
  • [48] EFFECTS OF ODANACATIB ON BMD AND SAFETY IN THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN PREVIOUSLY TREATED WITH ALENDRONATE- A RANDOMIZED PLACEBO-CONTROLLED TRIAL
    Palacios, S.
    Bonnick, S.
    De Villiers, T.
    Chapurlat, R.
    Odio, A.
    Scott, B.
    De Tilleghem, C. Le Bailly
    DaSilva, C.
    Leung, A.
    Gurner, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 136 - 136
  • [49] The effect of alendronate treatment on urinary calcium exretion in women with postmenopausal osteoporosis
    Ochodnicky, M
    Ochodnická, E
    Galajda, P
    Vladar, L
    Mokáñ, M
    OSTEOPOROSIS INTERNATIONAL, 2000, 11 : S191 - S192
  • [50] Alendronate treatment decreases urinary calcium excretion in women with postmenopausal osteoporosis
    Ochodnicky, M
    Ochodnicky, B
    Ochodnicka, E
    Galajda, P
    Vladár, L
    Mokán, M
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S36 - S36
12345